Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta‑analysis
Special Care in Dentistry · 2024
DOI: 10.1111/scd.12877 ↗At a glance
Metaanalyse in Special Care in Dentistry, 2024. Written by Chengrong Zhang and 11 co-authors. Institution: Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining…. Major MEDLINE topics: Denosumab, Bisphosphonate-Associated Osteonecrosis of the Jaw, Bone Density Conservation Agents, Diphosphonates. Cited 21 times so far (Crossref); 49 references. Funded by: Central Government Guiding Local Scientific and Technological Development Funds.
Abstract (original language)
Objectives
This study aimed to assess the overall incidence of osteonecrosis of the jaw (ONJ) caused by bisphosphonates and denosumab when used for controlling bone cancer metastasis or as adjuvant therapy. Subjects and Methods A systematic search of the PubMed, Embase, and Cochrane Library databases and major meetings’ proceedings as of July 30, 2022, identified randomized controlled trials (RCTs) and observational trials that evaluated ONJ caused by denosumab or bisphosphonates. The total incidence and risk ratio (RR) for ONJ were calculated using a random‐effects model.
Results
A total of 42 003 patients with various solid tumors reported in 23 RCTs were included. The overall ONJ incidence in cancer patients receiving denosumab or bisphosphonates was 2.08% (95% CI 1.37–2.91; p < .01; I 2 = 94.99%). Patients receiving denosumab had a higher ONJ incidence than those receiving bisphosphonates (RR 1.64, 95% CI 1.10–2.44; p < .05; I 2 = 65.4%). Subgroup analyses showed that prostate cancer patients receiving denosumab and receiving zoledronic acid had the highest ONJ incidences, 5.0% and 3.0%, respectively. The incidence of ONJ induced by different doses was also different.
Conclusions
The incidence of ONJ caused by denosumab and bisphosphonates is low, the dose of the drug and the type of cancer have certain influence on ONJ. Therefore, clinicians should use the drug reasonably to improve the quality of life of patients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Breast Disease Diagnosis and Treatment Center of Affiliated Hospital of Qinghai University & Affiliated Cancer Hospital of Qinghai University, Xining, China.
- Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.
ORCID profiles: Jiuda Zhao
Funding
- Central Government Guiding Local Scientific and Technological Development Funds
Cite
APA
Zhang, C., Shen, G., Li, H., Xin, Y., Shi, M., Zheng, Y., Wang, M., Liu, Z., Zhao, Y., Zhao, F., Ren, D., & Zhao, J. (2024). Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta‑analysis. Special Care in Dentistry. https://doi.org/10.1111/scd.12877
Vancouver
Zhang C, Shen G, Li H, Xin Y, Shi M, Zheng Y, et al. Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta‑analysis. Special Care in Dentistry. 2024. doi:10.1111/scd.12877
BibTeX
@article{Zhang2024,
author = {Zhang, Chengrong and Shen, Guoshuang and Li, Huihui and Xin, Yuanfang and Shi, Mingqiang and Zheng, Yonghui and Wang, Miaozhou and Liu, Zhen and Zhao, Yi and Zhao, Fuxing and Ren, Dengfeng and Zhao, Jiuda},
title = {Incidence rate of osteonecrosis of jaw after cancer treated with bisphosphonates and denosumab: A systematic review and meta‑analysis},
journal = {Special Care in Dentistry},
year = {2024},
doi = {10.1111/scd.12877}
}
EUVIMED